Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually:
Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021 at 3:30 pm ET
H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13, 2021 at 7:00 am ET
BofA Global Healthcare Conference on Thursday, September 16, 2021 at 10:05 am ET
Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 10:40 am ET
A live audio webcast of each presentation will be available on the Investors section of the Company's website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after each event.
About Alnylam
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the potential treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran) being developed and commercialized by Alnylam's partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its "Alnylam P5x25" strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.
We are thrilled to announce that Mary Beth Kirkpatrick, celebrated consultant and founder of Gaidge, has been honored with the 2024 Outstanding Contribution Award by the American Association of Orthodontists (AAO). This annual prestigious award...
Guardant Health, Inc. , a leading precision oncology company, today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will webcast a corresponding conference call...
Puma Biotechnology, Inc. , a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 2, 2024, following the release of its first quarter 2024 financial results.
The call may be accessed by dialing...
Revolve Technologies, a leader in innovative telecommunications solutions, today announced the appointment of Michael Keeler as President. Keeler brings more than two decades of expertise in global sales, leadership, and innovation, demonstrating a...
Xperi Inc. (the "Company" or "Xperi"), an entertainment technology company that invents, develops, and delivers technologies that enable extraordinary experiences, will announce first quarter 2024 financial results on Wednesday, May 8, 2024,...
Nextracker will announce its fourth quarter fiscal 2024 and full-year financial results after the market closes on Tuesday, May 14, 2024. The company will hold a conference call to discuss the results on the same day at 2:00 p.m. Pacific Time (5:00...